Curewell Capital Acquires Majority Stake in Wilmington PharmaTech

Wilmington PharmaTech (WPT), a manufacturer of small molecule active pharmaceutical ingredients (API) based in Newark, Delaware, has announced that it will receive a majority investment from the Los Angeles-based private equity firm, Curewell Capital. This strategic partnership is designed to accelerate WPT’s growth and enhance domestic pharmaceutical manufacturing capabilities.

Hui-Yin “Harry” Li, Ph.D., founder and CEO of Wilmington PharmaTech, will retain a significant ownership stake in the company and continue to lead its operations alongside the existing management team. The partnership is expected to inject substantial growth capital into WPT, enabling the company to expand its manufacturing capacity and improve its end-to-end API development and production services.

Founded in 2003, Wilmington PharmaTech has developed a reputation as a reliable partner for global drug developers. The company provides integrated services that encompass discovery, clinical development, and commercial-scale manufacturing. Its facilities span a 54-acre campus in Delaware, which includes two state-of-the-art buildings equipped with current Good Manufacturing Practices (cGMP) and high-potency API suites. Additionally, WPT operates a research and development center located in Suzhou, China.

Investment Aims to Meet Rising Demand

Dr. Li expressed optimism about the future, stating, “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies.” He emphasized the commitment to expanding WPT’s capabilities and capacity to better serve its global biopharmaceutical partners.

Curewell Capital partner Michael Dal Bello commended Wilmington PharmaTech’s scientific expertise and operational excellence. He highlighted that this investment aligns with the increasing demand for specialized pharmaceutical manufacturing in the United States. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity,” Dal Bello noted.

The transaction positions Wilmington PharmaTech to take advantage of the growing domestic and international demand for advanced API development. This partnership will likely bolster its role as a key manufacturing partner for biopharma innovators in the U.S.

As Wilmington PharmaTech embarks on this new chapter, the collaboration with Curewell Capital is set to enhance its operational capabilities, ultimately benefiting clients in the biopharmaceutical sector.